Market Overview

Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

Share:

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that Richard Rubino, Chief Financial Officer, will present in a fireside
chat discussion at the Canaccord Genuity Growth Conference on Thursday,
August 9, 2018 at 1:30 p.m. Eastern Time in Boston, MA. Mr. Rubino will
provide an Aerie overview and business update.

The fireside chat will be webcast live and may be accessed by visiting
Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retina diseases and
other diseases of the eye. Aerie's first product, Rhopressa®
(netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by
the U.S. Food and Drug Administration (FDA) for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension, was launched in the United States in April 2018.
In clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, cornea verticillata, instillation
site pain, and conjunctival hemorrhage. More information about Rhopressa®,
including the product label, is available at www.rhopressa.com.
Aerie's advanced-stage product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, achieved its 3-month primary
efficacy endpoint in two Phase 3 registration trials, Mercury 1 and
Mercury 2, and also showed safety and efficacy throughout 12 months in
Mercury 1. Aerie submitted the RoclatanTM New Drug
Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA
(Prescription Drug User Fee Act) goal date for the completion of the
FDA's review of the RoclatanTM NDA for March 14, 2019. Aerie
continues to focus on global expansion and the development of additional
product candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.

View Comments and Join the Discussion!